Washington DC-Baltimore Area
Senior commercial leader in biopharma services, with deep operating experience across CDMO, CRO, and platform companies. Track record built across two decades at global multinationals (Lonza, Catalent, Ginkgo Bioworks) and at growth-stage companies through senior C-level and Executive Chairman roles. Domain expertise spans biomanufacturing, biologics, cell & gene therapy, and AI-driven biopharma platforms — with particular depth in commercial strategy, international expansion, strategic partnerships, M&A, and operational transformation. Currently leading senior operating mandates at biopharma services companies in growth, transformation, and scale-up phases. Bilingual English/French, dual US/Canadian citizenship. PhD in Chemistry, MBA, Chemical Engineer. NACD Directorship Certified.
ArchiMed-backed biologics CDMO. Lead global commercial operations following the strategic and commercial reset. Concurrently served as Interim Executive Chairman during the commercial reset phase (concluded 2026); now focused on the commercial growth and business development phase — opening new accounts, structuring partnerships, and expanding the customer pipeline.
VC-backed pioneer in scalable transfection technology for cell and gene therapy manufacturing. Provide strategic and commercial leadership, working with the founding team to position the company for commercial scale-up and growth-stage financing. • Structured and closed commercial partnerships with industry players in cell & gene therapy manufacturing and bioproduction • Advanced multiple collaborations with cell & gene therapy developers and CDMOs • Lead fundraising strategy and investor engagement • Oversee technology development priorities aligned with cGMP and regulatory standards for clinical-stage manufacturing
AI-driven cell therapy company developing next-generation CAR-T, CAR-NK, and multi-specific immune therapies through Discovery 4.0, a foundational AI/ML platform that designs escape-resistant CAR constructs by jointly optimizing epitope selection, binder biophysics, multivalent architecture, and immune-cell suitability. Pipeline includes lead pre-IND programs in oncology and autoimmune indications (allogeneic mRNA-dualCAR-NK; autologous LVV-dualCAR-T), with clinical trials targeted for 2027. Provide board-level guidance on commercial strategy, partnership development, market positioning, investor relations, and long-term value creation. Support the founding team in scaling the platform and advancing strategic relationships with biopharma partners and investors.
Founder & Operating Partner of Innov2Gro — taking senior, full-accountability operating roles (CEO, CCO, Executive Chairman) at PE- and VC-backed biopharma and life sciences companies undergoing commercial transformation, accelerated growth, turnaround, restructuring, and scale-up. I selectively partner with companies that possess differentiated innovation and significant value-creation potential—whether the need is building commercial capabilities from the ground up or accelerating growth and market expansion. I lead the commercial engine directly, opening strategic accounts, structuring partnerships, optimizing commercial operations and organizational efficiency, and driving accelerated revenue growth, profitability, financing readiness, and long-term enterprise value creation. Focus areas: Biomanufacturing & CDMO | CRO | Cell & Gene Therapy | Synthetic Biology | Advanced Biologics | AI-Driven Biopharma Platforms Geographic scope: North America | Europe | Middle East
Continued in an advisory capacity following completion of the CEO turnaround mandate.
Took on the CEO role to transform a niche preclinical drug-testing technology provider (formerly TIM Company) into a recognized commercial CRO platform in the gut microbiome and drug-testing space. • Led the corporate rebrand and repositioned the SurroGUT™ platform as a highly realistic, human-relevant preclinical model — sharpening market identity and differentiation • Pivoted the business model from equipment sales to a CRO services portfolio built around the rebranded SurroGUT™ platform • Closed a strategic partnership with a Nasdaq-listed life sciences company, anchoring the new commercial direction • Secured FDA adoption of the SurroGUT™ platform • Signed multiple commercial and development agreements with leading global pharmaceutical and biotech organizations • Restructured the operating model and rebuilt the leadership team, bringing in dedicated local operational leadership while personally driving the commercial reset that put the company back on the path to profitability after six years of losses